Clay Siegall is the President, the Chief Executive Officer and also the Chairman of the Board of Seattle Genetics. He co-founded Seattle Genetics in 1998 with an aim of carrying out scientific innovation, holistic scientific research, drug development experiments and treating patients. Mr. Siegall is a scientist by profession and has majored in cancer therapies. Under his tenure, Seattle Genetics has developed into one of the leading companies to develop antibody-drug conjugates (ADCs). The company secured an FDA approval of it first ADC product called ADCETRIC (brentuximab vedotin) in 2011. Seattle Genetics joined hands with Takeda Pharmaceutical Company and made ADCETRIC a global brand approved in approximately 65 countries. The company is also developing a pipeline of ADCs for cancer treatment.
Thanks to Clay Siegall, Seattle Genetics has acquired strategic licenses for the ADC technology with other companies like Genentech, Pfizer, GlaxoSmithKline, and AbbVie. These strategic licenses have generated approximately 350 million USD. Additionally, other internal and collaborator programs have developed 20 clinical ADCs using the Seattle Genetics technology. Before co-founding Seattle Genetics, Clay Siegall worked with the Bristol-Myers Squibb Pharmaceutical Research Institute. From 1988 to 1991, he also worked with the National Cancer Institute and National Institute of Health. Currently, Mr. Siegall sits on Ultragenyx Pharmaceutical, Washington Roundtable, and Alder BioPharmaceuticals Boards of Directors.
His success and work has earned him several awards like the University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences in 2013. He was also the recipient of the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year. He has written more than 70 publications and is holder of 50 patents. Clay Siegall attended the University of Maryland where he graduated with a Bachelor of Science degree in Zoology. He also holds a Ph.D. in Genetics from George Washington University. Clay Siegall was inspired to establish Seattle Genetics after he saw his father succumb to cancer. He therefore wanted to develop a cancer treatment center that would facilitate the treatment of cancer by inventing and improving cancer tools to oncologists. Being an entrepreneur, Mr. Seagall’s strategy of collaborating with other companies in oncology drug development has enhanced the success of his business.